GYEONGGI-DO

Dreaming of Becoming a Global Centennial Company

with Unique Technology

 

 

 

 

Q.Please introduce EOFlow.

 

「Leading the global medical device market with electroosmosis technology」

 

A. EOFlow, founded in 2011, takes its name from the initial letters of Electro Osmosis, which refers to electroosmosis technology. The company creates products that deliver various medications using this technology and currently sells the EOPatch, a patch-type insulin pump.

Launched in April 2021, EOPatch helps diabetes patients manage their condition healthily. EOFlow, an innovative medical device manufacturer, has received several awards, including being recognized as one of the best companies to work for in Gyeonggi Province.

 

Q. What is the current state of the industry?

 

「Diabetes treatment market currently dominated by diabetes management devices」

 

A. In the past, diabetes treatment was primarily led by oral medications and self-monitoring blood glucose devices. When oral medications were insufficient, Multiple Daily Injections (MDI) of insulin were used. However, from the 2010s onwards, Continuous Glucose Monitoring Systems (CGMS) became widespread. This led to the popularity of Continuous Subcutaneous Insulin Infusion (CSII), also known as insulin pump therapy. Currently, the global diabetes treatment market is dominated by CGMS and insulin pumps.

 

Q. Please describe the features and advantages of the product.

 

「World’s second, Korea’s first patch-type insulin pump」

 

A. Many companies have attempted to develop patch-type insulin pumps, but only two, including us, have succeeded in commercializing them worldwide. Compared to traditional insulin pumps, our product is compact, lightweight, and wireless, making it beneficial for active diabetes patients. It simplifies insulin delivery compared to injection therapy, enabling proactive blood glucose management. In addition, unlike conventional pumps that require dedicated devices, EOFlow’s EOPatch is an innovative medical device that can be controlled via a smartphone.

 

Q. What are the plans for overseas market expansion, future business direction, or vision?

 

「To play a key role in the global insulin pump market」

 

A. In 2019, we signed an agreement for exclusive supply in Europe worth KRW 150 billion over five years with Menarini, one of the world’s top 50 pharmaceutical companies. Since 2022, we have been selling our products in Europe. In addition, we have signed sales agreements in the UAE and Indonesia and are in discussions with many other international buyers for export opportunities.

The global insulin pump market is currently dominated by Insulet and Medtronic. Leveraging our unique electroosmosis technology, EOFlow aims to become a centennial company, playing a key role in the global market.

 

http://www.eoflow.com/eng/main/main.html